LabGenomics KRX:084650KOSDAQ
랩지노믹스 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days4
DART filings, 7 days5
Articles tracked12since Sep 11
In Q2 2026, LabGenomics reported revenue of ₩15.8bn, down 29.4% year on year, and an operating loss of ₩6.9bn. LabGenomics (랩지노믹스) appeared in 4 Korean news articles and 5 DART filings over the past seven days. Coverage peaked on Sep 23 with 7 articles. The most common catalyst was clinical & approvals (2). It was most often mentioned alongside LDT and L&C Bio.
Filing signals 4 quarters of losses Insider selling Screener
LabGenomics quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩15.8bn | -29.4% | −₩6.9bn margin −43.6% | −₩2.5bn |
| Q1 2026 | ₩17.9bn | -18.1% | −₩4.2bn margin −23.3% | −₩4.7bn |
| Q4 2025 derived | ₩20.9bn | -5.3% | −₩25.5bn margin −122.0% | −₩40.9bn |
| Q3 2025 | ₩23.0bn | +6.4% | −₩2.1bn margin −9.2% | −₩3.5bn |
| Q2 2025 | ₩22.3bn | +0.3% | −₩20.2bn margin −90.4% | −₩14.7bn |
| Q1 2025 | ₩21.9bn | +10.1% | −₩5.7bn margin −26.1% | −₩5.4bn |
| Q4 2024 derived | ₩22.1bn | +10.7% | −₩5.6bn margin −25.6% | −₩12.3bn |
| Q3 2024 | ₩21.7bn | +2.2% | −₩3.8bn margin −17.6% | −₩2.7bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
LabGenomics top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4
- 5
- 6
Latest LabGenomics news Korean headlines
-
랩지노믹스, 美 뉴저지서 '위장관 검사 LDT' 승인
1 more on this story · 1 outlets
- 랩지노믹스, 美 뉴저지 ‘위장관 검사 LDT’ 승인 획득더스탁 · Sep 30 14:55
-
랩지노믹스, 사업구조 재편 효과 가시화…美 매출 늘고 손실 축소
1 more on this story · 1 outlets
- 랩지노믹스, 美 사업 매출 늘고 손실 줄었다…사업 재편 효과 가시화메디컬투데이 · Sep 23 12:38